文献速递药物相互作用治疗药物监测与药物基因组学

卡马西平CYP3A4诱导潜力评估:两项临床DDI研究与PBPK建模

Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling.
PubMed 文献 · Clin Pharmacol Ther · 2024-01-08

两项开放标签、固定序列、交叉临床药理学研究以咪达唑仑为敏感CYP3A4底物,在健康志愿者中评估卡马西平(滴定至300 mg bid×10天)的CYP3A4诱导作用,咪达唑仑AUC(0-∞)分别降低71.8%和67.7%,内部建立的PBPK模型充分描述该效应,卡马西平安全耐受,支持其作为利福平的替代强指数诱导剂用于DDI研究。

要点

  • 因利福平亚硝胺杂质问题不宜用于健康志愿者研究,卡马西平可作替代强CYP3A4诱导剂。
  • 内部建立的卡马西平PBPK模型已向科学界免费开放,可用于DDI风险评估。

核心结论

  • 卡马西平在300 mg bid×10天方案下具有强CYP3A4诱导作用,可作为利福平的替代强指数诱导剂用于临床DDI研究。

研究设计与样本

  • 两项开放标签、固定序列、交叉临床药理学研究在健康志愿者中以咪达唑仑为敏感CYP3A4底物评估卡马西平。
  • 卡马西平从100 mg bid滴定至200 mg bid,最终300 mg bid连续10天。

主要发现

  • 研究1中咪达唑仑AUC(0-∞)平均降低71.8%(比值0.282,90%CI 0.235–0.340)。
  • 研究2中咪达唑仑AUC(0-∞)平均降低67.7%(比值0.323,90%CI 0.256–0.407)。
  • 内部建立的卡马西平PBPK模型充分描述该诱导效应,并已向科学界免费开放。
  • 卡马西平在研究剂量方案下于健康参与者中安全且耐受良好。

临床怎么用

  • 在健康志愿者DDI研究中,可用卡马西平(滴定至300 mg bid×10天)替代利福平作为强CYP3A4指数诱导剂。
  • 可利用已开放的卡马西平PBPK模型支持药物开发中的DDI风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the past, rifampicin was well-established as strong index CYP3A inducer in clinical drug-drug interaction (DDI) studies. However, due to identified potentially genotoxic nitrosamine impurities, it should not any longer be used in healthy volunteer studies. Available clinical data suggest carbamazepine as an alternative to rifampicin as strong index CYP3A4 inducer in clinical DDI studies. Further, physiologically-based pharmacokinetic (PBPK) modeling is a tool with increasing importance to support the DDI risk assessment of drugs during drug development. CYP3A4 induction properties and the safety profile of carbamazepine were investigated in two open-label, fixed sequence, crossover clinical pharmacology studies in healthy volunteers using midazolam as a sensitive index CYP3A4 substrate. Carbamazepine was up-titrated from 100 mg twice daily (b.i.d.) to 200 mg b.i.d., and to a final dose of 300 mg b.i.d. for 10 consecutive days. Mean area under plasma concentration-time curve from zero to infinity (AUC(0-∞)) of midazolam consistently decreased by 71.8% (ratio: 0.282, 90% confidence interval (CI): 0.235-0.340) and 67.7% (ratio: 0.323, 90% CI: 0.256-0.407) in study 1 and study 2, respectively. The effect was adequately described by an internally developed PBPK model for carbamazepine which has been made freely available to the scientific community. Further, carbamazepine was safe and well-tolerated in the investigated dosing regimen in healthy participants. The results demonstrated that the presented design is appropriate for the use of carbamazepine as alternative inducer to rifampicin in DDI studies acknowledging its CYP3A4 inductive potency and safety profile.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kanefendt F, Dallmann A, Chen H, et al. Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling. Clin Pharmacol Ther. 2024. PMID: 38105467. doi:10.1002/cpt.3151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。